Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
About XOMA Royalty Corporation
XOMA Royalty Corporation (NASDAQ: XOMA) is a biotechnology royalty aggregator that plays a pivotal role in advancing the development of innovative therapeutic solutions. The company specializes in acquiring the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. By doing so, XOMA provides non-dilutive, non-recourse funding to biotech firms, enabling them to accelerate the development of their internal drug pipelines or meet other corporate objectives.
Business Model and Operations
XOMA's business model is centered around acquiring royalty and milestone rights from therapeutic assets across all stages of development. These assets span a wide range of therapeutic areas, including oncology, rare diseases, women's health, and cardio-respiratory conditions. By focusing on royalty aggregation rather than direct drug development, XOMA minimizes operational risks while maximizing potential financial returns. The company’s portfolio includes rights to commercial products such as VABYSMO®, OJEMDA™, MIPLYFFA™, and DSUVIA®, as well as a pipeline of investigational compounds with significant market potential.
Industry Significance
Operating at the intersection of biotechnology and finance, XOMA serves as a critical enabler for biotech innovation. Its royalty aggregation model provides biotech companies with the financial flexibility to advance groundbreaking therapies without the burden of equity dilution or traditional debt. This unique approach not only supports the development of life-saving treatments but also allows XOMA to build a diversified portfolio of assets that generate sustainable cash flows over time.
Portfolio and Market Position
XOMA boasts an extensive and growing portfolio of over 70 assets, including both commercial and investigational therapies. The company's portfolio strategy emphasizes diversification across therapeutic areas and stages of development, thereby mitigating risks associated with the inherently unpredictable nature of drug development. Recent acquisitions, such as economic interests in seralutinib for pulmonary arterial hypertension and XACIATO™ for bacterial vaginosis, highlight XOMA's commitment to expanding its asset base while addressing unmet medical needs.
Competitive Differentiation
XOMA differentiates itself through its expertise in asset valuation, strategic capital deployment, and risk diversification. Unlike traditional biotech firms that focus on drug development, XOMA’s royalty aggregation model allows it to benefit from the success of multiple therapeutic candidates without bearing the direct costs and risks of R&D. This positions XOMA as a trusted financial partner for biotech companies and a unique investment opportunity within the biotech sector.
Challenges and Risk Management
While XOMA's business model reduces operational risks, it is not without challenges. The company’s revenue streams depend on the successful development, regulatory approval, and market adoption of its partnered assets. To mitigate these risks, XOMA employs a disciplined approach to asset selection, focusing on therapies with strong clinical and commercial potential. Its diversified portfolio further helps to balance the inherent uncertainties of the biotech industry.
Conclusion
In summary, XOMA Royalty Corporation represents a unique and innovative approach to supporting biotech innovation. By acquiring royalty and milestone rights, the company enables the development of life-saving therapies while building a diversified and sustainable revenue model. With its extensive portfolio, strategic focus, and financial expertise, XOMA continues to play a crucial role in advancing human health and shaping the future of biotechnology.
XOMA Corporation, a biotechnology royalty aggregator, announced that its Chairman and CEO, Jim Neal, will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference. The event is scheduled for March 7, 2022, at 1:30 PM ET. Investors can access the presentation live or via a replay on the company's website for 90 days post-event. XOMA plays a crucial role in advancing human health by acquiring potential future economics from pre-commercial therapeutic candidates, boasting a portfolio of over 70 assets.
XOMA Corporation (Nasdaq: XOMA) announced that its CEO, Jim Neal, will present at the Aegis Capital Corp Virtual Conference on February 24, 2022 at 11:00 AM ET. This event runs from February 23-25, 2022, showcasing biotech advancements. The presentation will be accessible via Aegis and on XOMA's investor relations website, with a replay available for 90 days. XOMA, a biotechnology royalty aggregator, specializes in acquiring future economics linked to drug candidates, helping biotech firms with funding to advance their projects.
XOMA Corporation announced cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Preferred Stock will receive $0.53906 per share, while holders of the 8.375% Series B Cumulative Preferred Stock will receive $0.52344 per depositary share. These dividends will be paid on January 18, 2022, to shareholders of record as of January 4, 2022. XOMA continues to play a unique role in biotechnology by acquiring future economic rights to therapeutic candidates, supporting funding for developers.
XOMA Corporation (Nasdaq: XOMA) announced that CEO Jim Neal will present at two upcoming investor conferences. The first is the Biotech Showcase 2022, taking place virtually from January 10-12 and January 17-19, 2022, where Neal will participate in a fireside chat titled, “Royalty Licenses: An Economic Asset Often Ignored” on January 10 at 10:30 AM PT. The second conference is the H.C. Wainwright BioConnect Virtual Conference, held January 10-13, 2022, with a presentation available on-demand starting January 10 at 4:00 AM PT.
XOMA Corporation has appointed Jim Neal as Chairman of the Board, who will continue in his role until a new CEO is selected. Former Chairman, W. Denman Van Ness, will serve as Lead Independent Director. XOMA's portfolio includes over 70 assets in various stages of development, with significant recent milestones, including a $35 million payment from Novartis for advancing a candidate to Phase 3. XOMA maintains a debt-free balance sheet and expects to have nearly $100 million in cash following the Novartis milestone, positioning the company for continued growth.
XOMA Corporation (Nasdaq: XOMA) has announced a significant development as NIS793, an anti-TGFβ monoclonal antibody, progresses to Phase 3 trials, triggering a $35 million milestone payment from Novartis. The trial aims to evaluate NIS793's efficacy and safety in treating first-line metastatic pancreatic ductal adenocarcinoma. NIS793 has also received Orphan Drug Designation from the FDA. This milestone is part of a potential $410 million in milestone payments from Novartis, with tiered royalties on future sales based on successful commercialization.
XOMA Corporation reported Q3 2021 financial results, noting total revenues of $0.9 million, a rise from $0.6 million in Q3 2020. A $0.5 million milestone was earned from Compugen after AstraZeneca dosed the first patient in a study of AZD2936. R&D expenses were $30,000, while G&A expenses increased to $4.3 million. The net loss expanded to $4.4 million from $1.1 million a year earlier. XOMA held $68.8 million in cash at quarter-end, down from $84.2 million at the end of 2020, yet confident it can fund operations for multiple years.
XOMA Corporation (NASDAQ: XOMA) announced that CEO Jim Neal will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 28, 2021, at 10:20 AM PT. As a biotechnology royalty aggregator, XOMA plays a crucial role in advancing health by acquiring future economics from pre-commercial therapies, providing non-dilutive funding for biotech companies. The company manages over 70 assets linked to therapeutic candidates, enhancing its portfolio and potential revenue streams. Visit www.xoma.com for more details.
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its preferred stockholders. The holders of the 8.625% Series A Cumulative Perpetual Preferred Stock will receive a dividend of $0.53906 per share. Holders of the 8.375% Series B Cumulative Perpetual Preferred Stock will receive $0.52344 per depositary share. These dividends will be paid on or about October 15, 2021, to shareholders on record as of October 1, 2021.
XOMA Corporation announced that CEO Jim Neal will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. The presentation will be available on demand starting September 13, 2021, at 7:00 AM ET. Interested parties can access it through the link or via XOMA's investor relations section. A replay will be available for 90 days.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
What does XOMA Royalty Corporation do?
How does XOMA generate revenue?
What is XOMA's business model?
What therapeutic areas does XOMA focus on?
What makes XOMA unique in the biotech industry?
What are some commercial assets in XOMA's portfolio?
How does XOMA mitigate risks in its business model?
Who benefits from XOMA's royalty aggregation model?
What role does XOMA play in the biotech industry?
What is XOMA's approach to portfolio management?
